Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Iovance Biotherapeutics (IOVA) over the last 14 years, with Q3 2025 value amounting to $125.8 million.

  • Iovance Biotherapeutics' Total Current Liabilities changed N/A to $125.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $125.8 million, marking a year-over-year change of. This contributed to the annual value of $122.3 million for FY2024, which is 1091.06% up from last year.
  • Iovance Biotherapeutics' Total Current Liabilities amounted to $125.8 million in Q3 2025.
  • Over the past 5 years, Iovance Biotherapeutics' Total Current Liabilities peaked at $129.2 million during Q2 2025, and registered a low of $83.2 million during Q1 2024.
  • In the last 3 years, Iovance Biotherapeutics' Total Current Liabilities had a median value of $110.3 million in 2023 and averaged $106.7 million.
  • In the last 5 years, Iovance Biotherapeutics' Total Current Liabilities crashed by 465.2% in 2024 and then surged by 4744.27% in 2025.
  • Quarter analysis of 3 years shows Iovance Biotherapeutics' Total Current Liabilities stood at $110.3 million in 2023, then rose by 10.91% to $122.3 million in 2024, then rose by 2.82% to $125.8 million in 2025.
  • Its Total Current Liabilities stands at $125.8 million for Q3 2025, versus $129.2 million for Q2 2025 and $122.7 million for Q1 2025.